Tyrosine Kinase Inhibitors Display Potent Activity against Cryptosporidium parvum.

Nava, Maria G; Calderón, Félix; Fernández, Elena; Ballell, Lluis; Bamborough, Paul; Vinayak, Sumiti

Nava, Maria G; Calderón, Félix; Fernández, Elena; Ballell, Lluis; Bamborough, Paul; Vinayak, Sumiti.

Afiliação

Nava MG; Department of Pathobiology, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
Calderón F; Global Health, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Fernández E; Global Health, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Ballell L; Global Health, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Bamborough P; Molecular Design, GlaxoSmithKline, Stevenage, Herts, United Kingdom.
Vinayak S; Department of Pathobiology, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.

Microbiol Spectr ; 11(1): e0387422, 2023 02 14.

Article em En | MEDLINE | ID: mdl-36533912

Assuntos

Criptosporidiose; Cryptosporidium parvum; Cryptosporidium; Animais; Humanos; Criança; Pré-Escolar; Criptosporidiose/tratamento farmacológico

Palavras-chave

Cryptosporidium; anti-parasitic compounds; cryptosporidiosis; kinase library screening; protozoan parasite; tyrosine kinase inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cryptosporidium parvum / Criptosporidiose / Cryptosporidium Limite: Animals / Child / Child, preschool / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google